Trials / Completed
CompletedNCT00344773
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
An Open-label, Multi-centre Study to Evaluate Efficacy and Safety of Gefitinib as the First-line Treatment for Locally Advanced (IIIB), Metastatic (IV) or Recurrent Pulmonary Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the overall objective tumor response rate (ORR) of Gefitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib | 250mg tablet oral tablet once daily |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2006-06-27
- Last updated
- 2010-06-29
- Results posted
- 2010-06-04
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00344773. Inclusion in this directory is not an endorsement.